To determine DFS and Overall Survival in all patients with muscle-invasive bladder and upper-tract urothelial carcinoma treated with adjuvant MK-3475 (pembrolizumab) vs. observation.

Patients with muscle invasive and locally advanced urothelial cancer will be randomized to receive the study drug Pembrolizumab or Observation following their surgery.

Clinical Program: Urological Oncology Program
Cancer Type & Condition: Bladder Cancer
Principal Investigator: Jianqing Lin
Contact Info: 2029940450